Akero Therapeutics Inc’s recently made public that its President and CEO Cheng Andrew unloaded Company’s shares for reported $78001.0 on Mar 12 ’25. In the deal valued at $44.88 per share,1,738 shares were sold. As a result of this transaction, Cheng Andrew now holds 654,324 shares worth roughly $29.33 million.
Then, Young Jonathan sold 607 shares, generating $27,242 in total proceeds. Upon selling the shares at $44.88, the Chief Operating Officer now owns 200,540 shares.
Before that, Yale Catriona sold 614 shares. Akero Therapeutics Inc shares valued at $27,556 were divested by the Chief Development Officer at a price of $44.88 per share. As a result of the transaction, Yale Catriona now holds 95,034 shares, worth roughly $4.26 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 1.52% to $44.82. Over the last five days, the stock has gained 7.53%. Akero Therapeutics Inc shares have risen nearly 61.11% since the year began. Nevertheless, the stocks have risen 60.24% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $42.09, while 200 days put it at $30.99.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 44.00, which if violated will result in even more drops to 43.17. On the upside, there is a resistance level at 45.52. A further resistance level may holdings at 46.21. The Relative Strength Index (RSI) on the 14-day chart is 48.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.43, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.10%. Stochastics %K at 37.60% indicates the stock is a holding.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-02-28, growing by 1.42 million shares to a total of 5.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 3.63 million shares. There was a rise of 28.19%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
